The 10 that are cited most themselves, of 24.
Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision
The applicant submits, in essence, that, in requiring evidence of the ‘superiority’ of iloperidone over other second line medicinal products for schizophrenia, the contested decision infringes the principle of conferral, the principle …
19 Dec 2019 · 62018TJ0211
Arrêt du Tribunal (septième chambre) du 7 mars 2013. Acino AG (anciennement Acino Pharma GmbH) contre Commission européenne.Decision
Außerdem ist nach Art. 81 Abs. 1 der Verordnung Nr. 726/2004, der die allgemeine Begründungspflicht des Art. 296 Abs. 2 AEUV ausdrücklich aufgreift, jede Entscheidung zur Erteilung, Versagung, Änderung, Aussetzung, Rücknahme oder zum …
7 Mar 2013 · 62010TJ0539
Judgment of the Court (Sixth Chamber), 10 April 2014. Acino AG v European Commission.Decision
In paragraph 125 of the judgment under appeal, the General Court pointed out that Article 81(1) of Regulation No 726/2004, under which all decisions to grant, refuse, vary, suspend, withdraw or revoke a marketing authorisation are to state …
10 Apr 2014 · 62013CJ0269
Order of the President of the General Court of 29 February 2024. Neuraxpharm Pharmaceuticals SL v European Commission.Decision
In the fifth place, concerning the applicant’s assertion that (i) the condition relating to urgency is satisfied on the ground that the contested decision is manifestly illegal and (ii) the applicant would suffer irreparable damage …
29 Feb 2024 · 62023TO1182
Order of the President of the General Court of 19 July 2023. Zaklady Farmaceutyczne Polpharma S.A. v European Commission.Decision
Moreover, that letter does not refer to the MA granted to the applicant. It should be noted in that regard that Article 81 of Regulation No 726/2004 provides that any decision to vary or revoke an MA must state in detail the reasons on …
19 Jul 2023 · 62023TO0228
Order of the President of the General Court of 19 July 2023. Mylan Ireland Ltd v European Commission.Decision
Moreover, that letter does not refer to the MA granted to the applicant. It should be noted in that regard that Article 81 of Regulation No 726/2004 provides that any decision to vary or revoke an MA must state in detail the reasons on …
19 Jul 2023 · 62023TO0227
Order of the President of the General Court of 19 July 2023. Neuraxpharm Pharmaceuticals SL v European Commission.Decision
Moreover, that letter does not refer to the MA granted to the applicant. It should be noted in that regard that Article 81 of Regulation No 726/2004 provides that any decision to vary or revoke an MA must state in detail the reasons on …
19 Jul 2023 · 62023TO0226
Order of the President of the General Court of 29 February 2024. Mylan Ireland Ltd v European Commission.Decision
In the fifth place, concerning the applicant’s assertion that (i) the condition relating to urgency is satisfied on the ground that the contested decision is manifestly illegal and (ii) the applicant would suffer irreparable damage …
29 Feb 2024 · 62023TO1181
Order of the President of the General Court of 29 February 2024. Zakłady Farmaceutyczne Polpharma S.A. v European Commission.Decision
In the fifth place, concerning the applicant’s assertion that (i) the condition relating to urgency is satisfied on the ground that the contested decision is manifestly illegal and (ii) the applicant would suffer irreparable damage …
29 Feb 2024 · 62023TO1183
Order of the General Court (Ninth Chamber) of 12 October 2026. Merck Europe BV v European Commission.Decision
… Under Article 81(2) of Regulation No 726/2004, a marketing authorisation may not be granted, refused, varied, suspended, withdrawn or revoked except through the procedures and on the grounds set out in that regulation.
12 Oct 2026 · 62025TO0637(01)